CVac
CVac, short for ‘Cancer Vaccine’, is a potential immunotherapeutic agent that developed in Australia. CVac works by attaching an adjuvant, mannan, to the tumor cell surface protein MUC1, a glycoprotein commonly expressed on a variety of cancers. CVac is often compared to the immunotherapeutic agent Provenge, which gained FDA approval in 2010.
CVac
CVac, short for ‘Cancer Vaccine’, is a potential immunotherapeutic agent that developed in Australia. CVac works by attaching an adjuvant, mannan, to the tumor cell surface protein MUC1, a glycoprotein commonly expressed on a variety of cancers. CVac is often compared to the immunotherapeutic agent Provenge, which gained FDA approval in 2010.
has abstract
CVac, short for ‘Cancer Vaccin ...... nts in their second remission.
@en
Link from a Wikipage to an external page
Wikipage page ID
35,431,425
Wikipage revision ID
722,226,165
subject
hypernym
comment
CVac, short for ‘Cancer Vaccin ...... h gained FDA approval in 2010.
@en
label
CVac
@en